SCHEDULE 13G 0002077247 XXXXXXXX LIVE Common Shares, no par value per share 02/03/2026 0001374339 ProMIS Neurosciences Inc. 74346M505 Suite 200, 1920 Yonge Street Toronto A6 M4S 3E2 Rule 13d-1(c) Trails Edge Capital Partners, LP DE 933477.00 0.00 933477.00 0.00 933477.00 N 9.9 IA PN See Item 4 for additional information. Trails Edge Biotechnology Master Fund, LP E9 933477.00 0.00 933477.00 0.00 933477.00 N 9.9 PN See Item 4 for additional information. Ortav Yehudai X1 933477.00 0.00 933477.00 0.00 933477.00 N 9.9 IN See Item 4 for additional information. ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street, Toronto, A6, M4S 3E2 This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers". The address for each Filer is 3455 Peachtree Road NE, 5th Floor, Atlanta, GA 30326. See Item 4 of the cover page of each Filer. Y As of February 3, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 933,477 shares (the "Shares") of Common Stock, no par value per share (the "Common Stock"), of ProMIS Neurosciences Inc. (the "Issuer"). The 933,477 Shares reported as beneficially owned on this Schedule 13G by each Filer consists of (i) 557,103 Shares held directly by Trails Edge Biotechnology, (ii) 376,374 Shares underlying warrants (the "Warrants") held directly by Trails Edge Biotechnology. The securities beneficially owned by each Filer excludes 180,729 Shares underlying Warrants which contain an issuance limitation that prohibits the holder from exercising the Warrants to the extent that after giving effect to such issuance after the exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the other Filers) would beneficially own in excess of 9.99% of the Shares outstanding immediately after giving effect to the issuance of the Shares issuable upon exercise of the Warrants. As a result, Trails Edge Biotechnology beneficially owns 9.9% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 9.9% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on approximately 8,967,740 shares of Common Stock outstanding, comprised of (i) 2,152,444 shares of Common Shares outstanding, following a one-for-twenty-five reverse stock split effective as of November 28, 2025 reported by the Issuer in Exhibit 99.1 to its Form 8-K filed with the SEC on November 24, 2025 and (ii) 6,815,296 shares of Common Stock reported by the Issuer as issued as of February 3, 2026 in the Issuer's Form 8-K filed with the SEC on January 30, 2026. 9.9% 933,477.00 0.00 933,477.00 0.00 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 1- Joint Filing Agreement Trails Edge Capital Partners, LP /s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai 02/10/2026 Trails Edge Biotechnology Master Fund, LP /s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai 02/10/2026 Ortav Yehudai /s/ Ortav Yehudai 02/10/2026